C.K. Cooper Analysts Downgrade Nabi Biopharmaceuticals (NABI) Shares to "Hold"
Monday, July 18, 2021 1:31 PM

Equities research analysts at C.K. Cooper downgraded shares of Nabi Biopharmaceuticals (NASDAQ: NABI) to a "hold" rating in a research note to investors on Monday.

Separately, analysts at Leerink initiated coverage on shares of Nabi Biopharmaceuticals in a research note to investors on Tuesday, May 24th. They set an "outperform" rating on the stock. Also, analysts at Zacks Investment Research upgraded shares of Nabi Biopharmaceuticals from an "underperform" rating to a "neutral" rating in a research note to investors on Friday, April 8th.

Shares of Nabi Biopharmaceuticals traded down 67.67% during mid-day trading on Tuesday, hitting $1.82. Nabi Biopharmaceuticals has a 52 week low of $4.64 and a 52 week high of $5.98. The stock's 50-day moving average is $5.20 and its 200-day moving average is $5.54. The company has a market cap of $76.7 million.

Nabi Biopharmaceuticals last announced its quarterly results on Thursday, May 5th. The company reported $0.05 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of ($0.18) EPS by $0.23. During the same quarter in the prior year, the company posted $0.11 earnings per share. The company’s quarterly revenue was down 32.80% on a year-over-year basis. On average, analysts predict that Nabi Biopharmaceuticals will post $0.31 EPS next quarter.

Nabi Biopharmaceuticals is a biopharmaceutical company focused on the development of vaccines addressing unmet medical needs in the areas of nicotine addiction and infectious disease. As of December 31, 2009, the Company’s product in development is Nicotine Conjugate Vaccine (NicVAX), a investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. NicVAX is an investigational therapeutic vaccine for smoking cessation. In November 2009, it sold its development product PentaStaph (Pentavalent S.aureus Vaccine), a new pentavalent vaccine designed to prevent S.aureus infections including those infections caused by antibiotic-resistant strains of S.aureus, to GlaxoSmithKline Biologicals S.A.(GSK). NicVAX is designed to stimulate the immune system to produce highly specific antibodies that bind to nicotine. PentaStaph is an investigational vaccine, including technology that it has licensed on an exclusive basis from the National Institutes of Health.

Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.Click here to register.